OptimizeRx Corp financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data OptimizeRx Corp files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	7.75	12.1	21.2	24.6	43.3	61.3	62.5	71.5	92.1	109
Cost of revenue			9	9.16	19.2	25.7	23.5	28.6	32.7	35.8
Gross profit	4.34	5.95	12.2	15.4	24.1	35.6	39	42.9	59.4	73.6
Research and development			0	1.6	0				0	0
Selling, general and administrative						27.7	33.5
Operating expenses	5.92	8.08	12	19.1	26.2	35.3	51.3	69.3	73.1	61.9
Operating income	-1.58	-2.13	0.18	-3.69	-2.14	0.36	-12.3	-26.4	-13.7	11.7
Interest expense								1.45	6.16	5.29
Interest income	0.04	0.03	0.05	0.29	0.07	0.02	0.85	2.19	0.33	0.35
Other non-operating income	0.04	0.03	0.05	-0.35	-0.07	0.02	0.85	1.24	-5.68	-4.74
Pre-tax income	-1.54	-2.1	0.23	-4.04	-2.21	0.38	-11.4	-25.2	-19.4	6.95
Income tax				-0.9				-7.6	0.73	1.82
Net income	-1.54	-2.1	0.23	-3.14	-2.21	0.38	-11.4	-17.6	-20.1	5.13
EBITDA	-1.35	-1.81	0.5	-2.41	-0.06	2.33	-10.3	-24	-9.38	16
EPS, basic	-0.15	-0.21	0.02	-0.23	-0.15	0.02	-0.64	-1.03	-1.10	0.28
EPS, diluted	-0.15	-0.21	0.02	-0.23	-0.15	0.02	-0.64	-1.03	-1.10	0.27
Shares, basic (weighted)	9.9	9.82	10.8	13.4	14.8	17.2	17.8	17.1	18.3	18.6
Shares, diluted (weighted)	9.9	9.82	11.9	13.4	14.8	17.7	17.8	17.1	18.3	19

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	7.03	5.12	8.91	18.9	10.5	84.7	18.2	13.9	13.4	23.4
Short-term investments							55.9		0	0
Receivables	1.95	3.43	6.46	7.42	17.9	24.8	22.2	36.3	38.2	37.8
Other current assets	0.08	0.26	0.36	0.87	4.46	5.63	2.28	3.19	2.38	2.85
Total current assets	10.2	8.81	15.7	27.1	32.9	115	98.6	54.3	54	64.7
Property, plant and equipment	0.17	0.17	0.15	0.18	0.15	0.14	0.14	0.15	0.15	0.11
Lease right-of-use assets				0.56	0.45	0.33	0.24	0.57	0.37	0.4
Goodwill			3.68	14.7	14.7	14.7	22.7	78.4	70.9	70.9
Intangible assets	0.77	0.64	2.77	13.9	12.1	10.6	13	6.19	45.5	40.8
Total assets	11.5	9.76	25.1	56.6	60.3	141	135	183	171	177
Accounts payable	0.37	0.46	0.41	0.49	0.62	0.61	1.55	2.23	2.16	1.64
Accrued liabilities	0.29	0.95	1.3	1.8	2.42	2.9	2.6	7.71	8.49	11.6
Deferred revenue	0.39	0.51	0.61	0.58	0.29	1.39	0.16	0.17	0.47	0.5
Short-term debt								2	2	4.26
Total current liabilities	3.67	3.54	4.23	6.11	10	9.37	8.4	17.9	18.7	21.3
Long-term debt								34.2	30.8	21.4
Lease liabilities				0.45	0.33	0.24	0.14	0.37	0.21	0.23
Total liabilities	3.67	3.54	6.6	11.8	10.4	9.61	8.54	56.8	54.2	48.6
Total debt								38.3	34.3	26.3
Paid-in capital	33.7	35.3	48.7	78.3	85.6	167	173	191	201	208
Retained earnings	-28.3	-30.4	-30.3	-33.4	-35.6	-35.3	-46.7	-64.3	-84.4	-79.2
Treasury stock							-0	-0	-0	-0
Other comprehensive income										0
Shareholders' equity	7.81	6.22	18.5	44.9	50	131	126	127	117	128
Total equity	7.81	6.22	18.5	44.9	50	131	126	127	117	128
Total liabilities and equity	11.5	9.76	25.1	56.6	60.3	141	135	183	171	177
Shares outstanding	9.91	9.77	12	14.6	15.2	17.9	18.3	18.2	18.5	18.8

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-1.54	-2.1	0.23	-3.14	-2.21	0.38	-11.4	-17.6	-20.1	5.13
Depreciation and amortization	0.24	0.32	0.32	1.28	2.08	1.97	2.02	2.4	4.33	4.33
Stock-based compensation	0.18	0.09	2.52	2.26	3.17	5.49	15.7	13.7	11.5	6.96
Deferred income tax								-7.7	0.15	1.22
Change in receivables	0.51	-0.37	-2.79	-0.63	-10.7	-6.99	2.28	-8.71	-2.17	0.46
Change in payables	-0.21	0.09	-0.08	-0.05	0.13	-0.01	0.94	-1.32	-0.07	-0.52
Cash from operations	-0.47	-1.48	0.79	-1.66	-6.31	0.73	10.7	-7.24	4.89	18.7
Capital expenditures	-0.18	-0.04	-0.03	-0.09	-0.07	-0.1	-0.08	-0.09	-0.11	-0.06
Acquisitions			-5.6	-8.99			-2	-82.9
Purchases of investments							-55.9	-163
Cash from investing	-0.35	-0.04	-5.69	-10.6	-0.12	-0.49	-58.2	-25.3	-0.45	0.07
Debt issued								37.7
Debt repaid								-1.71	-4	-8
Stock issued	0.45		8.16	21.3	2.49	70.7	1.07		0	0.35
Share buybacks	-0.81	-0.39					-20	-7.52
Cash from financing	-0.36	-0.39	8.69	22.2	-1.9	73.9	-19	28.2	-4.91	-8.8
Net change in cash	-1.17	-1.91	3.79	9.94	-8.34	74.2	-66.5	-4.36	-0.47	9.99
Free cash flow	-0.64	-1.52	0.76	-1.75	-6.38	0.63	10.6	-7.33	4.78	18.7
Interest paid	0							1.21	6.2	4.18
Income taxes paid	0			0.9				0.05	0.16	1.76

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $8.04 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	73.2%	Gross profit / revenue.
Operating margin	11.0%	Operating income / revenue.
EBITDA margin	15.4%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	6.9%	Pre-tax income / revenue.
Net margin	4.7%	Net income / revenue.
FCF margin	18.6%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	18.7%	Cash from operations / revenue.
Effective tax rate	32.1%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	3.5%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	2.8%	Net income / average total assets.
Return on invested capital (ROIC)	5.8%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue	8.1%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	0.1%	Capital expenditures / revenue.
D&A / revenue	4.3%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	18.8%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	20.6%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	20.4%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	23.9%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	23.6%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	25.0%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	282.8%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	20.7%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow growth, 1y	290.6%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	20.8%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y	9.7%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	0.6%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	20.8%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	3.4%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	9.5%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	24.0%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	3.9%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	2.2%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	5.1%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	5.58x	Current assets / current liabilities.
Quick ratio	5.03x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	2.48x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.15x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	12.0%	Total debt / total assets.
Liabilities / assets	20.2%	Total liabilities / total assets.
Net debt	-$4.4M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	-0.29x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	2.33x	Operating income / interest expense.
Working capital	$44.4M	Current assets - current liabilities.
Goodwill and intangibles / assets	66.7%	(Goodwill + intangible assets) / total assets.
Tangible book value	$21.5M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.60x	Revenue / average total assets.
Fixed asset turnover	809x	Revenue / average property, plant and equipment.
Receivables turnover	3.98x	Revenue / average receivables.
Days sales outstanding	92 days	365 x average receivables / revenue.
Days payables	18 days	365 x average accounts payable / cost of revenue.
FCF conversion	399.0%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	0.4%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$0.24	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$5.25	Revenue / diluted weighted shares.
FCF per share	$0.98	Free cash flow / diluted weighted shares.
Operating cash flow per share	$0.98	Cash from operations / diluted weighted shares.
Book value per share	$6.96	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$1.14	Tangible book value / shares outstanding.
Cash per share	$1.28	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$151.4M	Share price x shares outstanding.
Enterprise value	$147.0M	Market cap + total debt - cash - short-term investments.
P/E	32.9x	Market cap / net income. Only when net income is positive.
P/S	1.54x	Market cap / revenue.
P/B	1.16x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	7.04x	Market cap / tangible book value, when positive.
P/FCF	8.25x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	8.22x	Market cap / cash from operations, when positive.
EV/Sales	1.49x	Enterprise value / revenue.
EV/EBIT	13.5x	Enterprise value / operating income, when both are positive.
EV/EBITDA	9.68x	Enterprise value / EBITDA, when both are positive.
EV/FCF	8.01x	Enterprise value / free cash flow, when both are positive.
FCF yield	12.1%	Free cash flow / market cap.
Earnings yield	3.0%	Net income / market cap (the inverse of P/E).

What was OptimizeRx Corp's revenue in fiscal 2025?

OptimizeRx Corp reported revenue of $109.4M for fiscal 2025, 18.8% higher than the year before.

Was OptimizeRx Corp profitable in fiscal 2025?

Yes. Net income was $5.1M, a net margin of 4.7%.

How much free cash flow did OptimizeRx Corp generate in fiscal 2025?

Cash from operations of $18.7M minus capital expenditures of $58.0K left free cash flow of $18.7M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to OptimizeRx Corp